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Aims Abnormal exercise test deﬁned as the occurrence of exercise limiting symptoms, fall in blood pressure below base-
line, or complex ventricular arrhythmias is useful to predict clinical events in asymptomatic patients with aortic ste-
nosis (AS). The purpose of this study was to determine whether exercise-stress echocardiography (ESE) adds any
incremental prognostic value to resting echocardiography in patients with AS having a normal exercise response.
Methods
and results
One hundred and eighty-six asymptomatic patients with at least moderate AS and preserved LV ejection fraction
(≥50%) were assessed by Doppler-echocardiography at rest and during a maximum ramp semi-supine bicycle exer-
cise test. Fifty-one (27%) patients had an abnormal exercise test and were excluded from the present analysis. Among
the 135 patients with normal exercise test, 67 had an event (aortic valve replacement motivated by symptoms or
cardiovascular death) at a mean follow-up of 20+14 months. The variables independently associated with events
were: age ≥65 years [hazard ratio (HR) ¼ 1.96; 95% conﬁdence interval (CI): 1.15–3.47; P ¼ 0.01], diabetes,
(HR ¼ 3.20; 95% CI: 1.33–6.87; P ¼ 0.01), LV hypertrophy (HR ¼ 1.96; 95% CI: 1.17–3.27; P ¼ 0.01), resting
mean gradient .35 mmHg (HR ¼ 3.60; 95% CI: 2.11–6.37; P , 0.0001), and exercise-induced increase in mean
gradient .20 mmHg (HR ¼ 3.83; 95% CI: 2.16–6.67; P , 0.0001).
Conclusion The exercise-induced increase in transvalvular gradient may be helpful to improve risk stratiﬁcation in asymptomatic
AS patients with normal exercise response. These results thus suggest that ESE may provide additional prognostic
information over that obtained from standard exercise testing and resting echocardiography.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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The management of asymptomatic patients with severe aortic
stenosis (AS) remains controversial. According to ESC and AHA/
ACC guidelines, only patients having severe AS associated with
either symptoms and/or LV ejection fraction ,50% have a class I
indication for aortic valve replacement (AVR).
1,2 However, the
slow progressive nature of AS combined to the relatively old
†These authors contributed equally to the realization of the study and the preparation of the manuscript.
* Corresponding author. Tel: +1 418 656 8711 (ext 5938), Fax: +1 418 656 4602, Email: philippe.pibarot@med.ulaval.ca (P.P.); Tel: +33 3 20 44 5331, Fax: +33 3 20 44 6504,
Email: ennezat@yahoo.com (P.V.E.)
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org.
The online version of this article has been published underanopen accessmodel. Users areentitled to use, reproduce,disseminate,ordisplaythe open accessversionof this article for
non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original
place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be
clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
European Heart Journal (2010) 31, 1390–1397
doi:10.1093/eurheartj/ehq076age of the population affected by this disease predispose to
under-reporting and/or underestimation of symptoms. Further-
more, sudden deaths have been reported in patients with severe
AS in the absence of previous report of symptoms.
3,4
In addition, Rosenhek et al.
5 showed that a substantial pro-
portion of patients with moderate AS progresses rapidly to the
severe stage and these patients display excess mortality. Hence,
moderate AS is not necessarily a benign disease and may require
close follow-up and additional tests for prognostication.
In light of these ﬁndings, proper risk stratiﬁcation of AS patients
is crucial to determine: (i) the most appropriate time interval (i.e. 6,
12, or 24 months) between follow-up visits in the individual
patient; and (ii) the optimal timing for AVR. In this regard,
several factors have been proposed to identify the patients who
are at higher risk for rapid disease progression and occurrence
of adverse events including: higher peak jet velocity or gradient
and smaller aortic valve area measured by Doppler-
echocardiography,
5–7 higher degree of valve calciﬁcation measured
by echocardiography or computed tomography,
5,7,8 occurrence of
exercise-limiting symptoms on exercise stress test,
9–13 and elev-
ated plasma levels of natriuretic peptides.
14,15
Animportantproportion(.20%)ofthe ASpatientswhoclaimto
be asymptomatic exhibit exercise-limiting symptoms during exercise
testing and thesepatients have a worse outcome.
9–13 Hence, abnor-
malexercisetestdeﬁnedastheoccurrenceofexercise-limitingsymp-
toms or fall in blood pressure below baseline is useful to predict
clinical events in asymptomatic patients with AS and is now included
in the ESC
1 and AHA/ACC
2 guidelines as an indication for AVR.
However, whether or not exercise-stress echocardiography (ESE)
provides any incremental predictive value beyond that obtained
from standard exercise testing (i.e. without echocardiography)
remains relatively unexplored and controversial.
13,16 Lancellotti
et al.
12 demonstrated that an absolute increase in mean gradient
.18 mmHgduringexerciseisanindependentpredictorofrapidpro-
gression to symptoms onset in patients with asymptomatic severe
AS. On the other hand, Weisenberg et al.
17 reported that ESE has
limited added value to exercise testing alone in this population.
Given that the predictive value of abnormal exercise test is now
well established and incorporated in the guidelines, the objective of
this study was to determine if ESE adds any incremental value to
resting echocardiography in the subset of patients who have a
normal exercise response.
Methods
Study population
Doppler-echocardiographic and clinical data were prospectively col-
lected in 186 asymptomatic patients with at least moderate AS (aortic
valve area ,1.5 cm
2 and indexed aortic valve area ,0.9 cm
2/m
2) who
underwent ESE in four hospitals. Ninety-three patients were recruited
in three European hospitals and 42 in one Canadian Center. The data
of these four centres were pooled together and retrospectively ana-
lysed. Exclusion criteria were: (i) symptoms including dyspnoea,
angina, syncope, or heart failure; (ii) LV ejection fraction ,50%; (iii)
moderate/severe aortic or mitral regurgitation or mitral stenosis; (iv)
coronary artery disease (history of myocardial infarction or coronary
artery stenosis on coronary angiography); (v) known pulmonary
disease;(vi)atrialﬁbrillationorﬂutter;and(vii)inabilitytoperformphys-
ical exercise.
Clinical data
Clinical data included age, gender, history of smoking, documented
diagnosis of hypertension [patients receiving antihypertensive medi-
cations or having known, but untreated, hypertension (blood pressure
≥140/90 mmHg)], hypercholesterolaemia (patients on cholesterol
lowering medication or in the absence of such medication low-density
lipoprotein cholesterol level . 160 mg dL
21), and diabetes (patients
currently receiving oral hypoglycaemic medication or insulin).
Exercise-stress echocardiography
Exercise protocol
A symptom-limited graded maximum bicycle exercise test was per-
formed in the semi-supine position on an ergometer table tilted to
208. After an initial workload of 20–25 W maintained for 3 min, the
workload was increased every 3 min by 20–25 W. A 12-lead ECG was
monitored continuously and blood pressure was measured at rest and
every 2 min during exercise. If patients were on beta-blocker, they
were asked to stop their medication 24 h before the test. The other
medications, if any, were left unchanged. Abnormal exercise test was
deﬁned as: (i) occurrence of limiting breathlessness or fatigue at low
workload, or of angina, dizziness, or syncope; (ii) fall in systolic blood
pressure below baseline; (iii) complex ventricular arrhythmia. Patients
with abnormal exercise test were excluded from the present study.
The maximum workload (Watts) was recorded and the percent of
maximum age and gender predicted workload was calculated.
18
Doppler-echocardiographic measurements
Doppler-echocardiographic data were obtained at rest and at peak
exercise with the use of a Vivid 7 (General Electrics, Chalfont St
Giles, UK) or Sonos 7500 (Philips, Andover, MA, USA) ultrasound
system and were stored in digital format for subsequent analysis.
The Doppler-echocardiographic measurements included the LV end-
diastolic diameter and thickness, the LV ejection fraction determined
by the modiﬁed biplane Simpson’s method, the transvalvular gradients
by the simpliﬁed Bernoulli equation, and the aortic valve area by the
continuity equation. For each measurement, at least three cardiac
cycles were averaged. The LV mass was calculated with the corrected
formula of the American Society of Echocardiography and indexed for
body surface area and LV hypertrophy was deﬁned as LV mass index
.115 g m
22 in men and .95 g m
22 in women.
Follow-up and study endpoint
The vast majority of the patients had an annual follow-up in the centre
where they had their baseline ESE. However, some patients were fol-
lowed by cardiologists in centres not participating to this study. In
these patients, the follow-up was performed by phone interview
with the patient and treating cardiologist. If an event occurred, it
was documented by review of patient’s chart.
The primary outcome variable was the time to occurrence of the
ﬁrst composite endpoint of cardiovascular death or need for AVR
motivated by the development of symptoms or LV systolic dysfunction.
Statistical analysis
Categorical data were given as a percentage and compared with a x
2
test. Continuous variables were tested for distribution normality
using the Shapiro–Wilk test. Continuous data were expressed as
mean+SD and compared using the two-sided Student’s t-test. Rest
and exercise echocardiographic data were compared using the
ESE for patients with aortic valve stenosis 1391paired Student’s t-test. If normality test failed, data were expressed as
median and interquartile range and compared using the two-sided Wil-
coxon’s rank-sum test.
Cumulative probability of event-free survival was estimated using
the Kaplan–Meier method and compared between groups using a
log-rank test. The effect of the clinical, Doppler-echocardiographic,
and exercise variables on event-free survival was assessed with the
use of Cox proportional hazard model. Proportionality of the hazard
was visually inspected from log-minus-log survival curves, stratiﬁed
by the variable of interest. Hazard proportionality was also assessed
by testing the interaction between variables of interest and time. All
the variables presented in Table 1 were tested in univariate analysis
and those with a P-value ,0.10 on univariate analysis were incorpor-
ated into the multivariate models. To avoid colinearity among a subset
of several variables measuring the same phenomenon (e.g. aortic valve
area and mean gradient), we entered in the multivariate models the
variable that had the strongest association with cardiac events on uni-
variate analysis. We constructed a ﬁrst series of multivariate models
with independent variables entered in continuous format and then a
second series with these variables entered in dichotomous formats.
A multivariate linear regression analysis was used to identify the
independent determinants of the exercise-induced changes in echocar-
diographic variables. A P-value , 0.05 was considered statistically
signiﬁcant. Statistical analyses were performed with the use of JMP
7.0.2 software.
Results
Among the 186 patients who underwent ESE, 51 (27%) had an
abnormal exercise test and were excluded from the present analy-
sis. Table 1 shows the baseline clinical, resting echocardiographic,
and ESE data of the study population composed of the 135 patients
who had a normal exercise test. This study population consisted of
87 (64%) men and 48 (36%) women with a mean age 64+15
years. The range of aortic valve area and indexed aortic valve
area was 0.42–1.50 cm
2 and 0.28–0.89 cm
2/m
2, respectively. Fifty-
three percent had a severe AS deﬁned as aortic valve area
,1.0 cm
2, 41% had LV hypertrophy, 47% had a history of
...............................................................................................................................................................................
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Table 1 Baseline clinical, exercise-stress, and Doppler-echocardiographic data at rest and at peak exercise in the whole
cohort (n 5 135)
Variables Rest Peak exercise
Follow-up duration (months) 20+14 –
Clinical data
Age (years) 64+15 –
Female gender, n (%) 48 (36) –
Body surface area (m
2) 1.8+0.2 –
Body mass index (kg/m
2)2 6 +4–
Hypertension, n (%) 63 (47) –
Diabetes, n (%) 13 (10) –
Hypercholesterolaemia, n (%) 50 (37) –
Exercise-stress data
Heart rate (b.p.m.) 71+12 126+24
a
Systolic blood pressure (mmHg) 138+21 178+27
a
Exercise duration (min) – 13+5
Peak workload (watt) – 90 (65–120)
b
Percent workload (%) – 73 (54–89)
b
ST segment depression ≥2 mm (%) – 14 (10%)
Doppler-echocardiographic data
Bicuspid valve 23 (17%) –
LV mass index (g/m
2) 105+34 –
LV hypertrophy, n (%) 55 (41) –
LV ejection fraction (%) 65+77 1 +10
a
LV stroke volume (mL) 83+17 85+22
a
Mean transvalvular ﬂow rate (mL/s) 269+55 345+87
a
Aortic valve area (cm
2) 0.97+0.22 1.07+0.27
a
Aortic valve area index (cm
2/m
2) 0.53+0.12 0.59+0.14
a
Peak aortic jet velocity (m/s) 3.8+0.8 4.5+0.8
a
Peak pressure gradient (mmHg) 61+24 82+27
a
Mean pressure gradient (mmHg) 36+15 49+19
a
aSigniﬁcant (P , 0.05) difference peak exercise vs. rest.
bValues are median (interquartile range).
S. Mare ´chaux et al. 1392hypertension, 37% had a history of hypercholesterolaemia, and
10% had diabetes. Left ventricular ejection fraction, stroke
volume, mean transvalvular ﬂow rate, aortic valve area, peak
aortic jet velocity, and transvalvular pressure gradients increased
signiﬁcantly during exercise (Table 1).
Analysis of outcome
Description of clinical events
Follow-up was complete in all patients. Mean follow-up time was
20+14 months (median 19 months). Sixty-seven (50%) patients
reached an endpoint during follow-up: 58 underwent AVR
motivated by development of symptoms; 1 had a sudden cardiac
arrest 12 months after ESE, was resuscitated, and underwent
AVR 3 weeks later; 4 developed severe symptoms but did not
undergo AVR because they had severe comorbidities and were
considered at prohibitive surgical risk; 1 developed severe symp-
toms and was waiting for surgery at the time of last follow-up;
and 3 died from cardiovascular causes at 20, 31, and 50 months
after ESE. All these deaths were preceded by the development
of symptoms: one patient developed severe dyspnoea (NYHA
class III) and died 2 months later from acute pulmonary
oedema; this patient was in poor general condition and was not
........................................................
...............................................................................................................................................................................
Table 2 Univariate analysis of association between baseline variables and event risk in the whole cohort (n 5 135) with
variables entered in continuous format
Variables Increment category Univariate analysis
HR (95% CI) P-value
Age (years) 10 years increase 1.33 (1.12–1.61)
a 0.001
Diabetes Yes 2.1 (0.90–4.10)
a 0.08
Rest systolic blood pressure 10 mmHg increase 1.10 (1.00–1.23)
a 0.06
LV mass index (g/m
2) 10 g/m
2 increase 1.12 (1.04–1.20)
a 0.004
Exercise LV ejection fraction (%) 10% decrease 1.22 (0.97–1.50)
a 0.09
Rest peak gradient (mmHg) 10 mmHg increase 1.22 (1.12–1.34) ,0.0001
Exercise peak gradient (mmHg) 10 mmHg increase 1.26 (1.15–1.38) ,0.001
Exercise D peak gradient (mmHg) 10 mmHg increase 1.24 (1.03–1.45) 0.04
Rest mean gradient (mmHg) 10 mmHg increase 1.44 (1.25–1.66)
a ,0.0001
Exercise mean gradient (mmHg) 10 mmHg increase 1.50 (1.30–1.72) ,0.0001
Exercise D mean gradient (mmHg) 10 mmHg increase 1.35 (1.05–1.72)
a 0.02
Rest aortic valve area (cm
2) 0.1 cm
2 decrease 1.27 (1.14–1.41) ,0.0001
Exercise aortic valve area (cm
2) 0.1 cm
2 decrease 1.14 (1.04–1.25) 0.004
This table shows the variables having a P-value ,0.10 on univariate analysis. The hazard ratio (HR) reﬂects the increase in risk of event per increment category: e.g. the risk of
event is increased by 1.44-fold per 10 mmHg increase in rest gradient.
aIndicates the variables that were entered in multivariate analysis (Table 3). Exercise D indicates absolute difference between peak exercise and rest data.
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Table 3 Multivariate analysis of association between baseline variables entered in continuous format and event risk in
the whole cohort (n 5 135), in patients with severe aortic stenosis (n 5 72), and in those with moderate aortic stenosis
(n 5 63)
Variables) Increment
category
Whole cohort (n 5 135) Severe aortic stenosis
(n 5 72)
Moderate aortic stenosis
(n 5 63)
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age (years) 10 years increase 1.27 (1.06–1.53) 0.01 1.17 (0.94–1.47) 0.16 1.82 (1.26–2.78) 0.001
Diabetes Yes 3.61 (1.49–7.83) 0.006 3.75 (1.39–9.12) 0.01 – –
Rest systolic blood pressure 10 mmHg increase 1.07 (0.92–1.22) 0.36 – – 1.17 (0.90–1.49) 0.23
LV mass index (g/m
2) 10 g/m
2 increase 1.08 (1.00–1.15) 0.06 1.12 (1.01–1.22) 0.02 – –
Rest mean gradient (mmHg) 10 mmHg increase 1.50 (1.27–1.77) ,0.0001 1.32 (1.05–1.86) 0.02 1.72 (1.03–2.86) 0.04
Exercise D mean gradient
(mmHg)
10 mmHg increase 1.67 (1.32–2.13) ,0.0001 1.49 (1.12–2.00) 0.008 2.08 (1.26–3.56) 0.004
Exercise LV ejection fraction (%) 10% decrease 1.20 (0.94–1.54) 0.15 1.22 (0.88–1.67) 0.23 – –
The variables marked by superscript ‘a’ in Table 2 were entered in the multivariate model for the whole cohort. We selected the same variables to construct the models in the
subsets of patients with severe and moderate aortic stenosis. However, the variables were entered in these models only if the P-value was ,0.1 on univariate analysis in the given
subset.
The hazard ratios reﬂect the increase in risk of event per increment category.
ESE for patients with aortic valve stenosis 1393referred to surgery by the treating physician. Two patients devel-
oped congestive heart failure: one died while waiting for surgery
and the other one was declined surgery because of severe comor-
bidities and died 2 months later. The median time between ESE
and occurrence of endpoint was 13 months (range: 0.6–50
months).
In addition, eight patients had censoring events which were not
considered as endpoints for this study. Five patients underwent
elective AVR not motivated by development of symptoms or LV
dysfunction; the reason for AVR was: rapid progression of stenosis
severity in two patients; aneurysm of ascending aorta in one; and
elective AVR prior to urologic surgery in one. Three patients
died of non-cardiovascular cause.
Analyses with variables expressed in continuous format
On univariate analysis, older age, increased LV wall thickness and
mass, smaller aortic valve area and higher transvalvular gradients
at rest, and larger increase in gradients during exercise were signiﬁ-
cantly (P , 0.05) associated with increased risk of event (Table 2).
Hazard proportionality was conﬁrmed for all variables. The exer-
cise duration, maximum exercise workload, percent of age and
gender predicted workload, peak exercise heart rate, change in
blood pressure, and occurrence of ST depression ≥2 mm during
exercise were not signiﬁcantly associated with clinical outcome.
On multivariate analysis including variables in continuous format
(Table 3), those independently associated with events were: older
age (P ¼ 0.01), diabetes (P ¼ 0.006), higher resting mean gradient
(P , 0.0001), and larger exercise-induced increase in mean gradi-
ent (P , 0.0001). Indexed LV mass and peak exercise LV ejection
fraction also had P-values of borderline signiﬁcance (P ¼ 0.06 and
0.15, respectively).
Importantly, the increase in mean gradient during exercise did
not correlate with the rest gradient (r ¼ 0.16; P ¼ 0.17) or with
any other rest echocardiographic data. The independent determi-
nants of larger exercise-induced increase in gradient were: younger
age (P ¼ 0.04), smaller increase in aortic valve area (P , 0.0001),
and larger increases in stroke volume (P , 0.0001) and heart
rate (P ¼ 0.004) during exercise. However, after further adjust-
ment for these variables in the multivariate model for the predic-
tion of event risk (Table 3), the signiﬁcance and hazard ratio (HR)
of exercise increase in gradient remained similar [P ¼ 0.001; HR ¼
1.64, 95% conﬁdence interval: 1.22–2.23].
Separate multivariate analyses in patients with moderate vs.
severe AS revealed that the exercise-induced increase in gradient
was strongly associated with event risk in both categories (Table 3).
Patients from the Canadian Center were signiﬁcantly younger
(60+13 vs. 65+15 years; P ¼ 0.03) and had lower prevalence
of severe AS (45 vs. 60%) compared with European Centers.
Adjustment for location of the participating centre (Canada vs.
Europe) in the multivariate model had no or minimal impact on
the signiﬁcance and HRs of the independent variables.
Analyses with variables expressed in dichotomous format
Univariate analyses with variables expressed in dichotomous
format revealed that age ≥65 years, rest systolic blood pressure
.135 mmHg, LV hypertrophy, resting mean gradient
.35 mmHg (Figure 1A), exercise-induced increase in mean
Figure 1 Event-free survival as a function of the level of rest
mean gradient (A), increase in gradient during exercise (B), and
combination of rest gradient and exercise-induced increase in
gradient (C). MG, mean gradient; Exer. DMG, exercise-induced
increase in mean gradient.
S. Mare ´chaux et al. 1394gradient .20 mmHg (Figure 1B), and peak exercise LV ejection
fraction ,70% were associated with increased risk of events. On
multivariate analysis including variable in dichotomous format
(Table 4), those independently associated with events were: age
≥65 years (HR ¼ 1.96; P ¼ 0.01); diabetes (HR ¼ 3.20; P ¼
0.01), LV hypertrophy (HR ¼ 1.96; P ¼ 0.01), resting mean gradi-
ent .35 mmHg (HR ¼ 3.60; P , 0.0001), and exercise-induced
increase in mean gradient .20 mmHg (HR ¼ 3.83; P , 0.0001).
There also was a strong trend for an association with peak exercise
LV ejection fraction ,70%.
When varying the cut-off value of rest gradient between 25 and
50 mmHg in this dichotomous model, the value of .35 mmHg
yielded to the highest P-value, x
2 of likelihood ratio, and HR. For
the exercise-induced increase in gradient, we used a cut-off value
of .20 mmHg that was close to the cut-off value (.18 mmHg)
proposed by Lancellotti et al.
12 With a cut-off value .18 mmHg,
the signiﬁcance and HR (P ¼ 0.002; HR ¼ 3.05) were slightly
inferior to those obtained with cut-off value .20 mmHg.
The combination of a rest gradient .35 mmHg and an
exercise-induced increase in gradient .20 mmHg was associated
with markedly increased risk of event (HR ¼ 9.6; P , 0.0001)
compared to the absence of these two factors (HR ¼ 1.0, referent
group) (Figure 1C). Patients with a rest gradient .35 mmHg and an
increase in gradient ≤20 mmHg during exercise had a 2.5-fold
increase in the risk of event compared with the referent group,
whereas those with a rest gradient ≤35 mmHg and an increase
in gradient .20 mmHg did not display a signiﬁcant increase in
event risk (HR ¼ 0.8; P ¼ NS). There were however very few
patients (n ¼ 9) in this latter group.
Discussion
The main ﬁnding of this study isthat ESE provides incremental prog-
nostic information beyond that obtained by resting echocardiogra-
phy or exercise testing alone. An increase in mean gradient
.20 mmHg during exercise was independently associated with a
3.8-fold increase in the risk of event after adjusting for other risk
factors including age, diabetes, LV hypertrophy, rest gradient, and
peak exercise LV ejection fraction. Moreover, patients having both
a rest gradient .35 mmHg and an exercise-induced increase in
gradient .20 mmHg display a 9.6-fold increase in the event risk
compared to 2.5-fold in patients with a rest gradient .35 mmHg
and a gradient augmentation ≤20 mmHg during exercise
(Figure 1C). Importantly, the exercise-induced increase in gradient
couldnotbepredictedfromtheclinicalorrestingechocardiographic
data.
Exercise stress vs. other predictors of
outcomes in aortic stenosis
Several of the risk factors identiﬁed in the present study including
older age, diabetes, LV hypertrophy, and higher transvalvular gradi-
ent have been reported in previous studies.
3,5–7 Previous studies
also demonstrated that abnormal exercise test is a powerful pre-
dictor of outcome.
9–11,13,16,19 Accordingly, current guidelines rec-
ommend surgery in asymptomatic patients with severe AS
exhibiting exercise-limiting symptoms (ESC: Class I; ACC/AHA:
IIb), fall in blood pressure (ESC: IIa, ACC/AHA: IIb), or occurrence
of complex ventricular arrhythmias (ESC: IIb) during exercise.
1,2 In
the present study that included only patients with a normal exer-
cise test, we found no signiﬁcant association between indices of
maximum exercise capacity (e.g. percent of age- and gender-
predicted workload) and outcome. Hence, as was found in 27%
of patients initially enrolled in this study, standard exercise
testing is useful to unmask symptoms in 20–30% of AS patients
who claim to be asymptomatic and this information is useful to
enhance prognostication. However, in the remaining group of
patients (70–80%) with normal response to exercise, the
measures of maximum exercise capacity fail to identify patients
at higher risk for rapid disease progression.
Incremental value of exercise-stress
echocardiography
Lancellotti et al.
12 previously demonstrated that an exercise-
induced increase in gradient .18 mmHg is an independent predic-
tor of outcome. Their study included a series of 69 patients of
whom 25 had abnormal exercise test. The present study extends
this previous observation by demonstrating that a large increase
in gradient during exercise is associated with a marked increase
in event risk even in the subset of patients with normal exercise
test, i.e. the patients with ‘true’ asymptomatic AS.
....................................... .......................................
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Table 4 Univariate and multivariate analysis of association between baseline variables and event risk in the whole
cohort (n 5 135) with variables entered in dichotomous format
Variables (%) of patients
with variable
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age ≥65 years 58 2.16 (1.30–3.72) 0.003 1.96 (1.15–3.47) 0.01
Diabetes 10 2.10 (0.90–4.10) 0.08 3.20 (1.33–6.87) 0.01
Rest systolic blood pressure .135 mmHg 55 1.71 (0.78–2.85) 0.03 1.30 (0.78–2.23) 0.32
LV hypertrophy 41 1.90 (1.17–3.08) 0.009 1.96 (1.17–3.27) 0.01
Rest mean gradient .35 mmHg 50 3.70 (2.21–6.41) ,0.0001 3.60 (2.11–6.37) ,0.0001
Exercise D mean gradient .20 mmHg 21 2.10 (1.22–2.52) 0.008 3.83 (2.16–6.67) ,0.0001
Exercise LV ejection fraction ,70% 38 1.61 (1.00–2.62) 0.05 1.61 (0.95–2.71) 0.07
ESE for patients with aortic valve stenosis 1395In a series of 50 patients, Marechaux et al.
20 also reported that
lower increase in LV ejection fraction is associated with abnormal
exercise test and higher incidence of cardiac events. This factor
was however not found to be associated with outcome in the
present series of patients with normal exercise response. None-
theless, there was a strong trend for an association between
reduced peak exercise LV ejection fraction and risk of events.
This index in fact incorporates the resting LV ejection fraction
and the exercise-induced ‘ejection’ reserve. In light of the results
of the present study, patients with a LV ejection fraction remaining
below 70% at peak exercise may be at higher risk of event. Inter-
estingly, reduced peak stress LV ejection fraction measured during
dobutamine echocardiography was found to be one of the main
independent risk factors for poor outcome in the series of patients
with low ﬂow, low gradient AS included in the TOPAS study.
21
Further studies are needed to conﬁrm the potential usefulness
of peak exercise LV ejection fraction for risk stratiﬁcation in
patients with asymptomatic AS.
Potential mechanisms underlying the
large exercise increase in gradient
A larger increase in gradient during exercise may reﬂect a more
severe stenosis. Indeed, the more severe is the stenosis at rest,
the higher is the increase in gradient for a given ﬂow rate during
exercise.
22,23 However, the fact that the exercise-induced increase
in gradient remained strongly associated with outcome even after
adjusting for the resting gradient may also suggest the implication
of other mechanisms such as differences in intrinsic valve compli-
ance. Hence, of two patients having the same valve oriﬁce area
at rest, the one with a non-compliant and rigid valve will exhibit
no or minimal enlargement in valve oriﬁce area (i.e. ﬁxed oriﬁce)
and a large increase in gradient during exercise, whereas the one
with residual valve compliance, i.e. with valve oriﬁce opening
reserve during exercise will have less pronounced increase in gra-
dient for a similar increase in ﬂow. And logically, the former patient
would be at higher risk for the rapid progression to symptoms and
events. In the present study, lower exercise-induced increase in
aortic valve area did not correlate with events. This ﬁnding may
be due to the larger variability inherent to the measurement of
aortic valve area, especially during exercise.
The higher increase in gradient during exercise may also be
related to a larger increase in stroke volume and transvalvular
ﬂow rate. The stroke volume often has a biphasic behaviour
during the course of exercise test: i.e. it may indeed increase mark-
edly at low workload levels and then plateau or decrease at higher
workloads due to tachycardia and associated reduction in LV dias-
tolic ﬁlling and pump function. Hence, a substantial increase in
stroke volume combined to a large increase in gradient may
reﬂect exercise termination at relatively low workload with early
and rapid rise in gradient due to a non-compliant stenotic valve.
In future studies, it would be interesting to determine if the kinetics
of the gradient increase during the exercise test (i.e. rapid rise in
the early exercise stages vs. progressive increase culminating in
the later stages) provides any incremental predictive value over
that obtained from the magnitude of the gradient augmentation
per se.
Clinical implications
This study is the ﬁrst to demonstrate the incremental prognostic
value of ESE in patients with normal exercise test. These ﬁndings
support the utilization of ESE rather than exercise testing alone
for prognostication in AS patients who claim to be asymptomatic.
In the subset of patients exhibiting abnormal exercise test (i.e.
‘false asymptomatic’ patients), AVR should be considered. In the
subset with normal exercise response (‘true asymptomatic’
patients), a large increase in gradient during exercise may help
identify patients who are at higher risk for rapid progression to
symptoms and events. In particular, this study reveals that patients
presenting with a rest gradient .35 mmHg and an
exercise-induced increase in gradient .20 mmHg have a very
high risk for event in the short-term (Figure 1C). Additional tests
such as measurement of plasma BNP may also be useful to
reﬁne risk stratiﬁcation in these patients
15 and future prospective
studies will be necessary to determine if prognosis of these
patients would be best served by closer watchful waiting
(e.g. q. 3–6 months) or earlier referral to surgery.
The results of this study suggest that ESE may help to improve
clinical management not only in patients with severe AS but also
in those with moderate AS. Several prospective studies revealed
that moderate AS is not a benign disease and that the outcome
is worse than commonly assumed.
5,24,25 Patients with moderate
AS, however, constitute a highly heterogeneous group of patients
with regard to the risk of adverse events: some patients indeed
remain event-free for several years, whereas others have a rapid
progression to symptoms and/or LV systolic dysfunction. Notwith-
standing this important inter-individual variability in disease pro-
gression rate, the most recent guidelines recommend an
echocardiographic follow-up every 2 years for patients with mod-
erate AS. In light of the data published in the literature,
5,24,25 it
would appear that this recommendation may not be appropriate
for all patients with moderate AS and that some of these patients
require more frequent and closer clinical and echocardiographic
follow-up. The results of the present study suggest that patients
with moderate AS presenting with a rest mean gradient
.35 mmHg and an exercise-induced increase in gradient
≤20 mmHg should have a follow-up at least every year, whereas
those with a rest gradient .35 mmHg and an increase in gradient
.20 mmHg should potentially have a follow-up every 6 months.
Hence, ESE may provide important incremental information that
may help the clinician to adjust and optimize the interval of
follow-up according to the predicted risk of event.
Limitations
Plasma BNP and valve calciﬁcation score were not systematically
measured in this study. These parameters have been shown to
be useful to predict stenosis progression and occurrence of
adverse events in asymptomatic AS.
5,7,8,15,26,27 The calciﬁcation
score measured by echocardiography has some limitations includ-
ing its semi-quantitative nature and the difﬁculty to standardize this
measurement among different centres and operators. Computed
tomography is probably superior to echocardiography for the
quantiﬁcation of valvular calciﬁcation, but the exposure to ionizing
radiation may limit its utilization for serial follow-up. Further
S. Mare ´chaux et al. 1396studies are needed to compare the predictive performance and
cost-beneﬁt ratio of these tests to those of ESE.
To perform several Doppler-echocardiographic measurements
at peak exercise is challenging and it is possible that the resulting
higher measurement variability may have limited our ability to
detect signiﬁcant association between some ESE variables, such
as peak exercise LV ejection fraction or exercise change in aortic
valve area, and the risk of events.
Conclusion
Indices of valve haemodynamic behaviour measured by ESE but not
indices of maximum exercise capacity are associated with outcome
in patients with true asymptomatic AS (i.e. with normal exercise
response). The exercise-induced increase in transvalvular gradient
may be helpful to improve risk stratiﬁcation in this population.
These results show that ESE provides important incremental prog-
nostic information that is unrevealed by standard exercise testing
or resting echocardiography. These ﬁndings support the utilization
of ESE for risk stratiﬁcation in asymptomatic AS patients.
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